Amphastar Pharmaceuticals (NASDAQ:AMPH) Downgraded to Hold Rating by StockNews.com

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) was downgraded by research analysts at StockNews.com from a "buy" rating to a "hold" rating in a note issued to investors on Friday.

AMPH has been the subject of a number of other reports. Piper Sandler decreased their target price on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating for the company in a research report on Thursday, August 8th. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Amphastar Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $63.00.

Amphastar Pharmaceuticals Trading Up 0.4 %

Shares of Amphastar Pharmaceuticals stock traded up $0.20 on Friday, hitting $50.73. 181,198 shares of the company traded hands, compared to its average volume of 391,857. The stock's 50 day moving average price is $48.24 and its 200-day moving average price is $43.77. The company has a market cap of $2.47 billion, a PE ratio of 16.21, a PEG ratio of 0.97 and a beta of 0.83. Amphastar Pharmaceuticals has a 52 week low of $36.56 and a 52 week high of $65.92. The company has a current ratio of 3.52, a quick ratio of 2.63 and a debt-to-equity ratio of 0.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.75 by $0.10. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. The business had revenue of $182.39 million for the quarter, compared to the consensus estimate of $171.29 million. Equities research analysts predict that Amphastar Pharmaceuticals will post 3.7 EPS for the current year.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 4,000 shares of the business's stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $48.35, for a total value of $193,400.00. Following the transaction, the executive vice president now directly owns 118,388 shares in the company, valued at $5,724,059.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, EVP Rong Zhou sold 4,000 shares of the company's stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $48.35, for a total transaction of $193,400.00. Following the sale, the executive vice president now directly owns 118,388 shares in the company, valued at approximately $5,724,059.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard K. Prins sold 17,101 shares of the business's stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $43.07, for a total value of $736,540.07. Following the sale, the director now owns 33,971 shares of the company's stock, valued at approximately $1,463,130.97. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 24,101 shares of company stock valued at $1,069,350. 27.10% of the stock is currently owned by insiders.

Institutional Trading of Amphastar Pharmaceuticals

Hedge funds have recently modified their holdings of the business. TD Asset Management Inc grew its holdings in Amphastar Pharmaceuticals by 67.4% in the second quarter. TD Asset Management Inc now owns 1,691,569 shares of the company's stock valued at $67,663,000 after purchasing an additional 680,976 shares during the last quarter. Epoch Investment Partners Inc. increased its stake in shares of Amphastar Pharmaceuticals by 35.1% during the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company's stock worth $43,154,000 after purchasing an additional 280,390 shares in the last quarter. American Century Companies Inc. lifted its stake in Amphastar Pharmaceuticals by 19.7% in the 2nd quarter. American Century Companies Inc. now owns 740,408 shares of the company's stock valued at $29,616,000 after buying an additional 121,764 shares in the last quarter. Millennium Management LLC grew its holdings in Amphastar Pharmaceuticals by 84.6% during the 2nd quarter. Millennium Management LLC now owns 738,748 shares of the company's stock valued at $29,550,000 after buying an additional 338,653 shares during the last quarter. Finally, Boston Trust Walden Corp purchased a new position in Amphastar Pharmaceuticals during the third quarter worth $26,189,000. 65.09% of the stock is owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.